The purpose of this study was to assess the efficacy of the SYSTANE® family of products (SYSTANE® Lid Wipes, SYSTANE® BALANCE Lubricant Eye Drops, and SYSTANE® Vitamins) on meibomian gland functionality in subjects with lipid deficiency related to evaporative dry eye as compared to the standard of care warm compresses.

Inclusion Criteria:

• Must have a clinical diagnosis of lipid deficient Evaporative Dry Eye;
• Meibomian Gland Functionality - Not more than 6 glands yielding liquid secretion;
• Must be willing to discontinue the use of all other Meibomian Gland; Dysfunction management prior to receiving the study test article at Visit 1, up until the end of the study period;
• Must have best corrected visual acuity of 20/40 Snellen or better in each eye;
• Must be able to follow instructions and be willing and able to attend required study visits;
• Must read, sign, and date an Ethics Committee reviewed and approved informed consent form;
• Other protocol-defined inclusion criteria may apply.

Exclusion Criteria:

• History or evidence of ocular or intraocular surgery or serious ocular trauma in either eye within the past 6 months;
• Current punctal occlusion of any type (e.g., collagen plugs, silicone plugs);
• History of intolerance or hypersensitivity to any component of the study medications;
• History or evidence of epithelial herpes simplex keratitis (dendritic keratitis); vaccinia; active or recent varicella viral disease of the cornea and/or conjunctiva; chronic bacterial disease of the cornea and/or conjunctiva and/or eyelids; mycobacterial infection of the eye; and/or fungal disease of the eye;
• Pregnant or lactating at the time of enrollment;
• Not willing to take adequate precautions not to become pregnant during the study;
• Use of any concomitant topical ocular medications during the study period;
• Use of systemic medications that may contribute to dry eye unless on a stable dosing regimen for a minimum of 30 days prior to Visit 1;
• Ocular conditions that may preclude the safe administration of either drop under investigation;
• Unwilling to discontinue contact lens wear during the study period and for at least 1 week prior to Visit 1;
• Participation in an investigational drug or device study within 30 days of entering this study;
• Other protocol-defined exclusion criteria may apply.

This reporting group includes all subjects who were enrolled and received at least one of the study treatments.

Adverse events (AEs) were collected for the duration of the study (4 months). This analysis group includes all enrolled and exposed subjects.

An AE is defined as any untoward medical occurrence in a subject who is administered a study treatment (i.e., initiation of treatment with test article) regardless of whether or not the event has a causal relationship with the treatment. AEs were obtained through volunteered and elicited comments by the participant.